MedTrace Logo

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

NCT02556307 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2016-02-15

Study results available
· View outcomes & findings →

Summary

In this Slovenian, multi-center, observational study, the effectiveness of standard of care Peginterferon alfa-2a + ribavirin treatment in adult patients with chronic hepatitis C (CHC) is examined. Patients were treated for 24- or 48-weeks, as prescribed by the treating physician, followed by a 24-week follow-up period.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.

DRUG

Ribavirin

Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556307 on ClinicalTrials.gov